Corvus Pharmaceuticals announced on June 4, 2025, the full 28-day data from Cohort 3 of its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The data confirmed earlier and deeper responses in Cohort 3 (200 mg twice per day, 400 mg total daily dose) compared to Cohorts 1 and 2.
At day 28, the mean reduction in EASI for Cohort 3 (n=12) was 64.8%, significantly separating from placebo (34.4% reduction). Clinically meaningful reductions in itch (≥4 points on PP-NRS) were observed in 50% of evaluable Cohort 3 patients by day 28, with onset as early as day 8. The overall data from Cohorts 1-3 showed a statistically significant improvement in EASI score for soquelitinib-treated patients compared to placebo at day 28 (p=0.036).
Following these results, the company initiated enrollment in an extension cohort of the Phase 1 trial, which will enroll 24 patients randomized 1:1 between active and placebo. This cohort will evaluate the 200 mg twice-daily dose for an extended 8-week treatment period, aiming to assess the potential for deeper responses with longer treatment duration and optimize the design for a planned Phase 2 trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.